CI
REGN icon

Cordant Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Cordant Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 344
2022
Q2 		– Sell
-14
Closed -$10K – 989
2022
Q1 		$10K Buy
+14
New +$8.86K 0.01% 120

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cordant Inc's REGN Position: Q2 2026 in Review

Cordant Inc held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 0 shares worth $100. The position accounts for ﹤0.01% of the portfolio, ranked #344.

Cordant Inc first reported a position in REGN in Q1 2022 and has held it in 1 quarter since. The position peaked at $10K in Q1 2022. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cordant Inc held 0 shares of Regeneron Pharmaceuticals worth $100 as of Q2 2026.
  • Cordant Inc left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Cordant Inc's portfolio in Q2 2026, its #344 holding.
  • Cordant Inc first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 1 quarter since.
  • Cordant Inc's Regeneron Pharmaceuticals position peaked at $10K in Q1 2022.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cordant Inc's 13F filing for Q2 2026, filed 15 Jul 2026.